Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee - Full Text View

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00652808

Purpose

This study was performed to demonstrate that treatment with valdecoxib 10 mg daily (QD) was at least as effective as with naproxen 500 mg twice daily (BID), a standard non-steroidal anti-inflammatory drug (NSAID), when taken for 6 weeks in Korean subjects with symptomatic osteoarthritis (OA) of the knee. Secondary objectives were to assess the overall safety and tolerability of valdecoxib 10 mg QD taken for 6 weeks in Korean subjects with symptomatic OA of the knee.

Condition	Intervention	Phase
Osteoarthritis Knee	Drug: valdecoxib Drug: naproxen	Phase III

MedlinePlus related topics: Osteoarthritis

Drug Information available for: Valdecoxib Naproxen Naproxen sodium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg QD and Naproxen 500 mg BID in Treating the Signs and Symptoms of Osteoarthritis of the Knee

Further study details as provided by Pfizer:

Primary Outcome Measures:

Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS) [ Time Frame: Week 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

WOMAC OA Physical Function [ Time Frame: Week 2 and Week 6 ] [ Designated as safety issue: No ]
WOMAC OA Stiffness Index [ Time Frame: Week 2 and Week 6 ] [ Designated as safety issue: No ]
Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS) [ Time Frame: Week 2 ] [ Designated as safety issue: No ]
Patient's Global Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS) [ Time Frame: Week 2 and Week 6 ] [ Designated as safety issue: No ]
adverse events [ Time Frame: Continuous ] [ Designated as safety issue: Yes ]
Physician's Global Assessment of Arthritis Pain [ Time Frame: Week 2 and Week 6 ] [ Designated as safety issue: No ]
WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Osteoarthritis (OA) Composite Index [ Time Frame: Week 2 and Week 6 ] [ Designated as safety issue: No ]
WOMAC OA Pain Index [ Time Frame: Week 2 and Week 6 ] [ Designated as safety issue: No ]

Enrollment:	265
Study Start Date:	May 2004
Study Completion Date:	September 2004

Arms	Assigned Interventions
Arm 1: Active Comparator	Drug: valdecoxib valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Arm 2: Active Comparator	Drug: naproxen naproxen 500 mg capsule by mouth twice daily for 6 weeks

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Korean outpatients with symptomatic radiologic evidence of OA of the knee (diagnosed according to the modified American College Rheumatology criteria)
Patient's Assessment of Arthritis Pain measurement of at least 40 mm on VAS
Patients had not received any NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the Baseline Visit

Exclusion Criteria:

Diagnosis of inflammatory arthritis, gout, pseudogout, Paget's disease, or any chronic pain syndrome that, in the Investigator's opinion, would interfere with the assessment of the Index Knee
Symptomatic anserine bursitis or acute joint trauma of the Index Knee
Arthroscopy performed on the Index Knee within the past 12 months
Complete loss of articular cartilage of the Index Knee
Administration of oral, or intramuscular, intravenous, or soft tissue injections of corticosterosteroids within 4 weeks prior to screening visit
Administration of intra-articular injection of corticosteroids or hyaluronic acid preparation in the Index Knee within 3 months or 6 months, respectively

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00652808

Locations

Korea, Republic of
Pfizer Investigational Site
Seoul, Korea, Republic of, 137-701
Pfizer Investigational Site
Seoul, Korea, Republic of, 110-744
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Pfizer Investigational Site
Anyang, Korea, Republic of, 431-070
Pfizer Investigational Site
Incheon, Korea, Republic of, 405-760
Pfizer Investigational Site
Pusan, Korea, Republic of, 602-739
Pfizer Investigational Site
Gwangju, Korea, Republic of, 501-757
Pfizer Investigational Site
Seoul, Korea, Republic of, 152-703

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Link to ClinicalStudyResults.org posting: This link exits the ClinicalTrials.gov site

Responsible Party:	Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	A3471045
Study First Received:	April 1, 2008
Last Updated:	April 7, 2008
ClinicalTrials.gov Identifier:	NCT00652808
Health Authority:	Unkown: Obtaining information and will provide once confirmed.

Keywords provided by Pfizer:

knee, OA patients

Study placed in the following topic categories:

Signs and Symptoms
Osteoarthritis, Knee
Naproxen
Musculoskeletal Diseases
Osteoarthritis

Joint Diseases
Arthritis
Rheumatic Diseases
Valdecoxib

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gout Suppressants
Pharmacologic Actions
Analgesics, Non-Narcotic

Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009